<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Molecular therapeutics &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/molecular-therapeutics/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 22 Jan 2026 11:53:05 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Molecular therapeutics &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Inhibiting CK2 Unleashes Neuroblastoma Treatment Potential</title>
		<link>https://bioengineer.org/inhibiting-ck2-unleashes-neuroblastoma-treatment-potential/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 22 Jan 2026 11:52:44 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CK2 Inhibition]]></category>
		<category><![CDATA[Makalenin içeriğine ve anahtar kelimelerine dayanarak en uygun 5 etiket: **Neuroblastoma Treatment]]></category>
		<category><![CDATA[Molecular therapeutics]]></category>
		<category><![CDATA[Molecular Therapy** **Açıklama:** 1. **Neuroblastoma Treatment:** Makalenin ana konusu olan nöroblastom tedavisi için doğrudan ve anahtar kelimelerde yer alan etiket. 2. **]]></category>
		<category><![CDATA[neuroblastoma treatment]]></category>
		<category><![CDATA[Pediatric Oncology]]></category>
		<category><![CDATA[Survivin Targeting]]></category>
		<guid isPermaLink="false">https://bioengineer.org/inhibiting-ck2-unleashes-neuroblastoma-treatment-potential/</guid>

					<description><![CDATA[A recent groundbreaking study has shed light on the intricate world of neuroblastoma, a malicious pediatric cancer that remains one of the foremost challenges in oncology. Researchers have unveiled a promising strategy to combat this malignancy by targeting a crucial protein known as survivin. This study, spearheaded by Cazzanelli, Dalle Vedove, Broso, and their associates, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319264</post-id>	</item>
	</channel>
</rss>
